• Explore /
  • Poster
  • / Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

Abstract Poster

Authors

null

Laurent Mhanna

University Hospital Toulouse (Larrey), Toulouse, France

Laurent Mhanna, Julie Milia, Amellie Lusque, Sebastien Couraud, Celine Mascaux, Remi Veillon, Martin Frueh, Denis Moro-Sibilot, Mickaël Lattuca-Truc, Pascale Tomasini, Fabrice Barlesi, Alexander E. Drilon, Oliver Gautschi, Julien Mazieres

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 172)

DOI

10.1200/JCO.2018.36.5_suppl.172

Abstract #

172

Poster Bd #

L5

Abstract Disclosures

Similar Posters

First Author: Kiyotaka Yoh

First Author: Karen Kelly

Poster

2022 ASCO Annual Meeting

Molecular characterization of NF1-mutated NSCLC and clinical outcomes.

Molecular characterization of NF1-mutated NSCLC and clinical outcomes.

First Author: Christopher Gates

First Author: Samuel Rosner